Generic and biosimilar drugs generated a record $408 billion for America’s patients and healthcare system in 2022. Generic medicines are an integral part of our health-care system, expanding patient access through competition and lower prices. And a new wave of lower-priced biosimilars is also delivering value and savings. This comes at a time when the focus has shifted to the recent surge in drug shortages. The findings in this report reinforce the critical importance of the often underappreciated generic and biosimilar industry to America’s patients. We encourage you to share them with your social network.
Advocate for Generics and Biosimilars

Find legislation in your area and send a message to your lawmaker to protect your access to affordable generic and biosimilar medicines.

- AAM Website: accessiblemeds.org
- Biosimilars Council Website: biosimilarscouncil.org
- Biosimilars Council Action Center: takeaction.accessiblemeds.org/Km29Tnr

Follow AAM on Social Media

Follow the Biosimilars Council
**Message**

We encourage you to include the hashtag "#GRxBiosimsSavingsReport" in your tweets and tag @accessiblemeds and @biosimilarscouncil in all posts so we can share your message!

**Social Images**

Download all images [here](#).

**Hashtags**

#GRxBiosimsSavingsReport  
#PatientAccess  
#Generics  
#GenericDrugs  
#GenericMedicines  
#Biosimilars  
#Biosimilar  
#DrugPricing  
#RemarkablyGeneric  
#4GRxANTED

If you need assistance, email the Communications department at: media@accessiblemeds.org
Annual savings from #generics & #biosimilars exceeded $408 billion in 2022, an increase of $35 billion from 2021. Because of their lower costs, #genericmedicines represent more than 90% of the prescriptions dispensed in the U.S. https://accessiblemeds.org/resources/reports/2023-savings-report #GRxBiosimsSavingsReport

Annual Savings From Generic and Biosimilar Medicines


Twitter

- Annual savings from #generics & #biosimilars exceeded $408 billion in 2022, an increase of $35 billion from 2021. Because of their lower costs, #genericmedicines represent more than 90% of the prescriptions dispensed in the U.S. https://accessiblemeds.org/resources/reports/2023-savings-report #GRxBiosimsSavingsReport

Facebook / LinkedIn

- Annual savings from #generics & #biosimilars exceeded $408 billion in 2022, an increase of $35 billion from 2021. Because of their lower costs, #genericmedicines represent more than 90% of the prescriptions dispensed in the U.S. View AAM’s #GRxBiosimsSavingsReport: https://accessiblemeds.org/resources/reports/2023-savings-report #patientaccess #remarklygeneric
90% of the 6.4 billion prescriptions filled in 2022 were for #generics and #biosimilars. However, they accounted for only 17.5% of spending on #Rx medicines. View the full #GRxBiosimsSavingsReport report from @accessiblemeds: https://accessiblemeds.org/resources/reports/2023-savings-report #patientaccess #remarklygeneric

Generic prices have been deflating and the overall value of all generic sales in the U.S. has declined by $6.4 billion since 2019 in spite of increased volume and new generic launches. https://accessiblemeds.org/resources/reports/2023-savings-report #GRxBiosimsSavingsReport #remarklygeneric
Despite making up more than 9 out of every 10 prescriptions, spending on generic medicines accounts for roughly 1.5% of total U.S. health care spending. Read more in AAM’s #GRxBiosimsSavingsReport: https://accessiblemeds.org/resources/reports/2023-savings-report #patientaccess #remarklygeneric
AAM’s #GRxBiosimsSavingsReport shows that generic and biosimilar medicines provide critical savings throughout the health care system. In 2022, the use of generics and biosimilars saved $130 billion in #Medicare. https://accessiblemeds.org/resources/reports/2023-savings-report #patientaccess #drugpricing #remarklygeneric
The average copay for #generic prescription is only $6.16, compared with the average brand copay of $56.12. View the full #GRxBiosimsSavingsReport report from @accessiblemeds: https://accessiblemeds.org/resources/reports/2023-savings-report #patientaccess #drugpricing #remarklygeneric

The average copay for #generic prescription is only $6.16, compared with the average brand copay of $56.12. View the full #GRxBiosimsSavingsReport report from AAM: https://accessiblemeds.org/resources/reports/2023-savings-report #patientaccess #drugpricing #remarklygeneric
### Savings by Condition

<table>
<thead>
<tr>
<th>CONDITION</th>
<th>TOTAL SAVINGS (PRIMARY CONDITION + COMORBIDITIES)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Heart Disease</td>
<td>$104.5 Billion</td>
</tr>
<tr>
<td>Anxiety and Depression</td>
<td>$60.5 Billion</td>
</tr>
<tr>
<td>Diabetes</td>
<td>$59.5 Billion</td>
</tr>
<tr>
<td>Epilepsy</td>
<td>$42.2 Billion</td>
</tr>
<tr>
<td>Allergies and Asthma</td>
<td>$11.3 Billion</td>
</tr>
<tr>
<td>Breast Cancer</td>
<td>$8.9 Billion</td>
</tr>
<tr>
<td>Parkinson’s Disease</td>
<td>$6.4 Billion</td>
</tr>
<tr>
<td>Alzheimer’s Disease</td>
<td>$6.2 Billion</td>
</tr>
<tr>
<td>Chronic Obstructive Pulmonary Disease (COPD)</td>
<td>$6.1 Billion</td>
</tr>
</tbody>
</table>


---

**Twitter**

- @accessiblemeds #GRxBiosimsSavingsReport shows that in 2022, #generics and #biosimilars generated $104.5B in savings for patients with #heartdisease, $60.5B for patients treating #mentalhealth, and $59.5B for persons living with #diabetes. https://accessiblemeds.org/resources/reports/2023-savings-report #remarklygeneric

---

**Facebook / LinkedIn**

- AAM’s #GRxBiosimsSavingsReport shows that in 2022, #generics and #biosimilars generated $104.5 billion in savings for patients with #heartdisease, $60.5 billion for patients treating #mentalhealth, and $59.5 billion for persons living with #diabetes. View full report: https://accessiblemeds.org/resources/reports/2023-savings-report #patientaccess #drugpricing #remarklygeneric
New analysis from AAM’s #GRxBiosimsSavingsReport shows that it takes 3 years for new #genericmedicines to be covered by 50% of #Medicare Rx plans, meaning that seniors pay more for longer than they should. Read more: https://accessiblemeds.org/resources/reports/2023-savings-report #patientaccess

New analysis from AAM’s #GRxBiosimsSavingsReport shows that it takes 3 years for new #genericmedicines to be covered by 50% of #Medicare Rx plans, meaning that seniors pay more for longer than they should. Read more: https://accessiblemeds.org/resources/reports/2023-savings-report #patientaccess #prescriptiondrugs #remarklygeneric
The average biosimilar price is more than 50% lower than the brand biologic price at the time of biosimilar launch. Since 2015, #biosimilars has saved U.S. patients nearly $24B. Read more in @accessiblemeds #GRxBiosimsSavingsReport: https://accessiblemeds.org/resources/reports/2023-savings-report #remarklygeneric

The average biosimilar price is more than 50% lower than the brand biologic price at the time of biosimilar launch. Moreover, biosimilar competition is forcing brand biologics to reduce their prices. Since 2015, the use of #biosimilars has saved U.S. patients nearly $24 billion. Read more in AAM’s #GRxBiosimsSavingsReport: https://accessiblemeds.org/resources/reports/2023-savings-report #remarklygeneric
To date, the FDA has approved over 42 biosimilars across 15 molecules. 36 biosimilars are on the market with prices averaging more than 50% less than the reference brand biologic price at launch. Read more in AAM’s #GRxBiosimsSavingsReport: https://accessiblemeds.org/resources/reports/2023-savings-report #GRxBiosimsSavingsReport #biosimilars @BiosimsCouncil